Revolutionizing MS Treatment: ENHANCE Study Shows Promising Results for BRIUMVI Infusions in Just 30 Minutes

Exciting Updates from TG Therapeutics, Inc. at ECTRIMS 2024 Infusion Related Reactions with BRIUMVI Recently presented data from the ENHANCE Phase 3b trial by TG Therapeutics, Inc. showcased the mild (Grade 1) infusion-related reactions experienced by patients receiving 30-minute BRIUMVI infusions. These reactions were found to resolve completely, highlighting the safety profile of this treatment….

Read More

Maximizing Returns: A Guide to Understanding Share Transactions in the Corporate World

Transaction in Own Shares 08 October, 2024 Shell plc Announces Share Purchase Shell plc (the ‘Company’) announces that on 08 October 2024 it purchased a significant number of Shares for cancellation. The aggregated information on Shares purchased according to trading venue is as follows: Date of purchase: 08/10/2024 Number of Shares purchased: 1,000,000 Highest price…

Read More